Orgenesis Inc. Announces Acquisition of Certain Neurocords LLC Assets, Strengthening its Regenerative Medicine Portfolio with Spinal Cord Injury Therapies
Orgenesis (OTCQX:ORGS) has acquired key assets from Neurocords focused on advanced regenerative medicine therapies for spinal cord injuries (SCI). The acquisition includes technology that differentiates induced pluripotent stem cells (iPSC) into spinal cord neurons using Orgenesis's decentralized cell processing approach.
The transaction involves Orgenesis issuing 1,200,000 shares of common stock to Neurocords. The global SCI treatment market, valued at $7.5 billion in 2023, is projected to reach $11.2 billion by 2031.
The integration combines Neurocords' technology with Orgenesis's MIDA Technology of AI-based generation of autologous stem cells, aiming to create an autologous neural cell production platform. This approach is designed to expedite capacity setup, enhance production efficiency, and reduce treatment costs, potentially making therapies more accessible to patients.
Orgenesis (OTCQX:ORGS) ha acquisito beni chiave da Neurocords focalizzati su terapie avanzate di medicina rigenerativa per lesioni del midollo spinale (SCI). L'acquisizione include tecnologia che differenzia le cellule staminali pluripotenti indotte (iPSC) in neuroni del midollo spinale utilizzando l'approccio decentralizzato di elaborazione cellulare di Orgenesis.
La transazione prevede che Orgenesis emetta 1.200.000 azioni di azioni ordinarie a Neurocords. Il mercato globale per il trattamento delle SCI, valutato 7,5 miliardi di dollari nel 2023, è previsto raggiungere 11,2 miliardi di dollari entro il 2031.
L'integrazione combina la tecnologia di Neurocords con la tecnologia MIDA di Orgenesis per la generazione basata sull'IA di cellule staminali autologhe, con l'obiettivo di creare una piattaforma di produzione di cellule neurali autologhe. Questo approccio è progettato per accelerare l'impostazione della capacità, migliorare l'efficienza produttiva e ridurre i costi di trattamento, rendendo potenzialmente le terapie più accessibili ai pazienti.
Orgenesis (OTCQX:ORGS) ha adquirido activos clave de Neurocords centrados en terapias avanzadas de medicina regenerativa para lesiones de la médula espinal (SCI). La adquisición incluye tecnología que diferencia las células madre pluripotentes inducidas (iPSC) en neuronas de la médula espinal utilizando el enfoque descentralizado de procesamiento celular de Orgenesis.
La transacción implica que Orgenesis emita 1.200.000 acciones de acciones ordinarias a Neurocords. El mercado global de tratamiento de SCI, valorado en 7.5 mil millones de dólares en 2023, se proyecta que alcance 11.2 mil millones de dólares para 2031.
La integración combina la tecnología de Neurocords con la tecnología MIDA de Orgenesis para la generación de células madre autólogas basada en IA, con el objetivo de crear una plataforma de producción de células neurales autólogas. Este enfoque está diseñado para acelerar la configuración de capacidad, mejorar la eficiencia de producción y reducir los costos de tratamiento, lo que potencialmente hace que las terapias sean más accesibles para los pacientes.
오르제네시스 (OTCQX:ORGS)는 척수 손상(SCI)을 위한 고급 재생 의학 치료에 중점을 둔 뉴로코드로부터 주요 자산을 인수했습니다. 이 인수에는 오르제네시스의 분산형 세포 처리 접근 방식을 사용하여 유도 다능성 줄기세포(iPSC)를 척수 뉴런으로 분화시키는 기술이 포함됩니다.
이번 거래는 오르제네시스가 뉴로코드에 1,200,000주의 보통주를 발행하는 것을 포함합니다. 2023년 75억 달러로 평가된 글로벌 SCI 치료 시장은 2031년까지 112억 달러에 이를 것으로 예상됩니다.
이 통합은 뉴로코드의 기술과 오르제네시스의 AI 기반 자가 줄기세포 생성 기술인 MIDA 기술을 결합하여 자가 신경 세포 생산 플랫폼을 만드는 것을 목표로 합니다. 이 접근 방식은 용량 설정을 가속화하고 생산 효율성을 높이며 치료 비용을 줄여, 환자들이 치료를 더 쉽게 받을 수 있도록 할 수 있습니다.
Orgenesis (OTCQX:ORGS) a acquis des actifs clés de Neurocords axés sur des thérapies avancées en médecine régénérative pour les lésions de la moelle épinière (SCI). L'acquisition comprend une technologie qui différencie les cellules souches pluripotentes induites (iPSC) en neurones de la moelle épinière en utilisant l'approche de traitement cellulaire décentralisée d'Orgenesis.
La transaction implique qu'Orgenesis émette 1.200.000 actions ordinaires à Neurocords. Le marché mondial du traitement des SCI, évalué à 7,5 milliards de dollars en 2023, devrait atteindre 11,2 milliards de dollars d'ici 2031.
L'intégration combine la technologie de Neurocords avec la technologie MIDA d'Orgenesis pour la génération de cellules souches autologues basée sur l'IA, visant à créer une plateforme de production de cellules neuronales autologues. Cette approche est conçue pour accélérer la mise en place de la capacité, améliorer l'efficacité de la production et réduire les coûts de traitement, rendant potentiellement les thérapies plus accessibles aux patients.
Orgenesis (OTCQX:ORGS) hat wichtige Vermögenswerte von Neurocords erworben, die sich auf fortschrittliche regenerative Medizintherapien für Rückenmarksverletzungen (SCI) konzentrieren. Der Erwerb umfasst Technologien, die induzierte pluripotente Stammzellen (iPSC) mithilfe des dezentralen Zellverarbeitungsansatzes von Orgenesis in Rückenmarksneuronen differenzieren.
Die Transaktion beinhaltet, dass Orgenesis 1.200.000 Aktien von Stammaktien an Neurocords ausgibt. Der globale Markt für SCI-Behandlungen, der 2023 mit 7,5 Milliarden US-Dollar bewertet wird, wird voraussichtlich bis 2031 11,2 Milliarden US-Dollar erreichen.
Die Integration kombiniert die Technologie von Neurocords mit der MIDA-Technologie von Orgenesis zur KI-basierten Erzeugung von autologen Stammzellen, mit dem Ziel, eine Plattform zur Produktion autologer neuronaler Zellen zu schaffen. Dieser Ansatz soll die Kapazitätseinrichtung beschleunigen, die Produktionseffizienz verbessern und die Behandlungskosten senken, wodurch potenziell Therapien für Patienten zugänglicher werden.
- Strategic entry into $7.5B spinal cord injury treatment market
- Technology acquisition enhances autologous cell therapy portfolio
- Decentralized processing approach reduces treatment costs
- Established clinical network through VA and key stakeholders
- Technology potentially applicable to additional neural indications
- Share dilution through issuance of 1.2M new shares
- No immediate revenue impact disclosed
- Clinical development stage technology without proven commercial success
Strategic Acquisition Designed to Expand Access to Cost-Effective, Scalable Regenerative Medicine Treatments
GERMANTOWN, MD / ACCESS Newswire / March 6, 2025 / Orgenesis Inc. (OTCQX:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today announced the acquisition of certain Neurocords LLC's ("Neurocords") assets related to advanced regenerative medicine therapies for spinal cord injuries (SCI). The global spinal cord injury treatment market size was valued at
Neurocords' technology now purchased by the Company, differentiates induced pluripotent stem cells (iPSC) into spinal cord neurons leveraging Orgenesis's decentralized approach to cell processing, which is designed to expedite capacity setup, enhance production efficiency, and reduce treatment costs. This allows therapies to reach a larger number of patients more cost-effectively and with better outcomes.
"Having an autologous SCI therapy is complementary to Orgenesis's existing portfolio of autologous cell therapeutic technologies. Neurocords' innovative research utilizing stem cell therapy for neural regeneration represents an important field of cell therapy," said Vered Caplan, CEO of Orgenesis. "By integrating the technology now purchased from Neurocords and combining this with our MIDA Technology of AI-based generation of autologous stem cells, we hope to provide an autologous neural cell production platform. This is an additional product that integrates into our decentralized cell processing approach, which we believe may accelerate development of this transformative technology as an affordable treatment for patients suffering from spinal cord injuries. The ability to generate autologous neurons may have use for additional indications."
Ross Mason, Chairman of Neurocords, added, "Neurocords has spent significant time developing technology to produce neurons for spinal cord injury treatment. Orgenesis has assisted us by providing its expertise in advancing this technology toward the clinical stage, and we have been highly impressed by their capability and dedication to making cell therapies both safe and affordable. They have been a committed partner, supporting our development efforts at every stage. Over the development period, we have built a large clinical network for spinal cord injury, working alongside the VA and other key stakeholders to ensure that patients worldwide have access to groundbreaking therapies."
The acquisition is structured as an equity transaction, with Orgenesis issuing 1,200,000 shares of common stock to Neurocords or its designated recipients in consideration for the purchased assets. Additional details about the transaction are available in the Company's form 8-K, which has been filed with the Securities and Exchange Commission and is available on the Company's website.
About Orgenesis
Orgenesis is a global biotech company that has been committed to unlocking the potential of cell and gene therapies (CGTs) since 2012 as well as a paradigm-shifting decentralized approach to processing since 2020. This new model allows Orgenesis to bring academia, hospitals, and industry together to make these essential therapies a reality sooner rather than later. Orgenesis is focusing on advancing its CGTs toward eventual commercialization while partnering with key industry stakeholders to provide a rapid, globally harmonized pathway for these therapies to reach and treat a larger number of patients more cost-effectively and with better outcomes through great science and decentralized production. Additional information about the Company is available at: www.orgenesis.com.
Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. These forward-looking statements involve substantial uncertainties and risks and are based upon our current expectations, estimates, and projections and reflect our beliefs and assumptions based on information available to us as of the date of this release. Forward-looking statements include, but are not limited to, statements regarding, the development and commercialization of our POCare platform, our pipeline, and our decentralized CGT platform. We caution readers that forward-looking statements are predictions based on our current expectations about future events and are not guarantees of future performance. Actual results, performance, or achievements may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, but not limited to, our reliance on our point-of-care cell therapy platform, our ability to achieve and maintain profitability, outcomes of clinical trials, timing of clinical trial completions, the potential uses of our product candidates, our ability to manage potential disruptions, sufficiency of working capital, and the risks and uncertainties discussed under the heading "Risk Factors" in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and other filings with the U.S. Securities and Exchange Commission. We undertake no obligation to revise or update any forward-looking statements for any reason.
IR contact for Orgenesis:
Crescendo Communications, LLC
Tel: 212-671-1021
Orgs@crescendo-ir.com
SOURCE: Orgenesis Inc
View the original press release on ACCESS Newswire
FAQ
What is the value of the Neurocords asset acquisition by ORGS in terms of shares?
How big is the spinal cord injury treatment market that ORGS is entering?
What technology did ORGS acquire from Neurocords in March 2025?
How will the Neurocords acquisition benefit ORGS's existing cell therapy platform?
What is the main advantage of ORGS's decentralized approach in the Neurocords technology?
